Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects

Neurology

Volumn 62, Issue 11, 2004, Pages 2092-2094

  Lampasona, V ^a   Franciotta, D ^b   Furlan, R ^a   Zanaboni, S ^a   Fazio, R ^a   Bonifacio, E ^a   Comi, G ^a   Martino, G ^a,c  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

ADOLESCENT; ADULT; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; ENCEPHALOMYELITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; WESTERN BLOTTING;

EID: 2942566404     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000127615.15768.AE     Document Type: Article

References (10)

1. Schluesener HJ, Sobel RA, Linington C, Weiner HL. A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol 1987;139:4016-4021.
2. Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999;5:170-175.
3. Stefferl A, Brehm U, Linington C. The myelin oligodendrocyte glycoprotein (MOG): a model for antibody-mediated demyelination in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neural Transm Suppl 2000;58:123-133.
4. Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003;349:139-145.
5. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13:227-231.
6. Furlan R, Brambilla E, Ruffini F, et al. Intrathecal delivery of IFN-γ protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J Immunol 2001;167:1821-1829.
7. Bonifacio E, Lampasona V, Bingley PJ. IA-2 (islet cell antigen 512) is the primary target of humoral autoimmunity against type 1 diabetes-associated tyrosine phosphatase autoantigens. J Immunol 1998;161: 2648-2654.
8. Reindl M, Linington C, Brehm U, et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain 1999;122:2047-2056.
9. Leslie D, Lipsky P, Notkins AL. Autoantibodies as predictors of disease. J Clin Invest 2001;1417-1422.
10. O'Connor KC, Chitnis T, Griffin DE, et al. Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interaction. J Neuroimmunol 2003;136:140-148.